OC-0924 Prostate RT In high risk or N+ Moderate vs Extreme hypofractionation (PRIME): An Interim analysis
Vedang Murthy(Homi Bhabha National Institute), Indranil Mallick(Tata Medical Center), B. Arun(Tata Medical Center), Venkatesh Rangarajan(Tata Memorial Hospital), Abhinav Agrawal, Gitanjali Panigrahi(Homi Bhabha National Institute), Gagan Prakash(Homi Bhabha National Institute), Aparna Katdare, Priyamvada Maitre(Homi Bhabha National Institute), S. Kannan, Santosh Menon(Homi Bhabha National Institute), Ankit Arora, Reena Phurailatpam(Tata Memorial Hospital), Mahendra Pal(Homi Bhabha National Institute), Ritesh Mhatre(Tata Memorial Hospital), Pooja Singh, Moses Arunsingh(Tata Medical Center)
Cited by 10
Related Papers
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
|European Urology|2017|644
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
|European Urology|2020|396
Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis
|European Journal of Nuclear Medicine and Molecular Imaging|2011|377
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial
|Journal of Clinical Oncology|2017|340